Zhou W, Yan T, Hu Z, Wu J, Zhou Y, Xie L
J Cancer. 2024; 15(20):6698-6709.
PMID: 39668823
PMC: 11632987.
DOI: 10.7150/jca.102760.
Fuchs K, Goransson M, Kester M, Ettienne N, van de Meent M, de Jong R
J Immunother Cancer. 2024; 12(12).
PMID: 39653555
PMC: 11629015.
DOI: 10.1136/jitc-2024-009564.
Alban T, Riaz N, Parthasarathy P, Makarov V, Kendall S, Yoo S
Nat Med. 2024; 30(11):3209-3222.
PMID: 39349627
DOI: 10.1038/s41591-024-03240-y.
Shapiro J, Corrado M, Perry J, Watts T, Bolotin S
Hum Vaccin Immunother. 2024; 20(1):2395679.
PMID: 39205626
PMC: 11364080.
DOI: 10.1080/21645515.2024.2395679.
Fischer F, Mucke J, Werny L, Gerrer K, Mihatsch L, Zehetmaier S
Virol J. 2024; 21(1):139.
PMID: 38877590
PMC: 11179387.
DOI: 10.1186/s12985-024-02411-0.
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mork S, Skadborg S, Albieri B, Draghi A, Bol K, Kadivar M
J Immunother Cancer. 2024; 12(5).
PMID: 38782542
PMC: 11116868.
DOI: 10.1136/jitc-2024-008817.
Simultaneous analysis of pMHC binding and reactivity unveils virus-specific CD8 T cell immunity to a concise epitope set.
Kristensen N, Dionisio E, Bentzen A, Tamhane T, Kemming J, Nos G
Sci Adv. 2024; 10(15):eadm8951.
PMID: 38608022
PMC: 11014448.
DOI: 10.1126/sciadv.adm8951.
Reassessing human MHC-I genetic diversity in T cell studies.
Slieker R, Warmerdam D, Vermeer M, van Doorn R, Heemskerk M, Scheeren F
Sci Rep. 2024; 14(1):7966.
PMID: 38575727
PMC: 10995142.
DOI: 10.1038/s41598-024-58777-2.
Cross-reactive CD8 T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs).
Cavalluzzo B, Viuff M, Tvingsholm S, Ragone C, Manolio C, Mauriello A
J Exp Clin Cancer Res. 2024; 43(1):87.
PMID: 38509571
PMC: 10953141.
DOI: 10.1186/s13046-024-03004-z.
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
Meyer M, Parpoulas C, Barthelemy T, Becker J, Charoentong P, Lyu Y
Front Immunol. 2024; 14:1294565.
PMID: 38239352
PMC: 10794645.
DOI: 10.3389/fimmu.2023.1294565.
Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
Shah R, Cygan E, Kozlik T, Colina A, Zamora A
Front Immunol. 2023; 14:1301100.
PMID: 38149253
PMC: 10749952.
DOI: 10.3389/fimmu.2023.1301100.
Combinatorial multimer staining and spectral flow cytometry facilitate quantification and characterization of polysaccharide-specific B cell immunity.
Hoving D, Marques A, Huisman W, Nosoh B, de Kroon A, van Hengel O
Commun Biol. 2023; 6(1):1095.
PMID: 37898698
PMC: 10613281.
DOI: 10.1038/s42003-023-05444-3.
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Giannakopoulou E, Lehander M, Virding Culleton S, Yang W, Li Y, Karpanen T
Nat Cancer. 2023; 4(10):1474-1490.
PMID: 37783807
PMC: 10597840.
DOI: 10.1038/s43018-023-00642-8.
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z, Klatt M, Dao T, Urraca J, Scheinberg D, OReilly R
J Immunother Cancer. 2023; 11(9).
PMID: 37775115
PMC: 10546156.
DOI: 10.1136/jitc-2023-006889.
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm S, Frej M, Rafa V, Hansen U, Ormhoj M, Tyron A
J Immunother Cancer. 2023; 11(8).
PMID: 37586765
PMC: 10432666.
DOI: 10.1136/jitc-2023-006847.
modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes.
Hulen T, Friese C, Kristensen N, Granhoj J, Holz Borch T, Peeters M
Front Immunol. 2023; 14:1180997.
PMID: 37359554
PMC: 10285209.
DOI: 10.3389/fimmu.2023.1180997.
Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials.
Arif S, Domingo-Vila C, Pollock E, Christakou E, Williams E, Tree T
Front Immunol. 2023; 14:1183909.
PMID: 37283770
PMC: 10240960.
DOI: 10.3389/fimmu.2023.1183909.
Antigen-specific and cross-reactive T cells in protection and disease.
Jiang N, Malone M, Chizari S
Immunol Rev. 2023; 316(1):120-135.
PMID: 37209375
PMC: 10524458.
DOI: 10.1111/imr.13217.
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Tsimberidou A, Guenther K, Andersson B, Mendrzyk R, Alpert A, Wagner C
Cancer Immunol Res. 2023; 11(7):925-945.
PMID: 37172100
PMC: 10330623.
DOI: 10.1158/2326-6066.CIR-22-0444.
Dynamics and specificities of T cells in cancer immunotherapy.
Oliveira G, Wu C
Nat Rev Cancer. 2023; 23(5):295-316.
PMID: 37046001
PMC: 10773171.
DOI: 10.1038/s41568-023-00560-y.